September 28, 2016 5:14 AM ET

Pharmaceuticals

Company Overview of Altiris Therapeutics, Inc.

Key Executives for Altiris Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Douglas H. Gooding 23 RelationshipsChief Executive Officer and President--
Dennis C. Liotta Ph.D.45 RelationshipsCo-founder, Chairman of Scientific Advisors and Director68
Hyunsuk Shim Ph.D.9 RelationshipsCo-Founder and Member of Scientific Advisors--
James P. Snyder Ph.D.19 RelationshipsCo-Founder and Member of Scientific Advisors--
Suzy Beckham Ph.D.No RelationshipsHead of Operations--

Altiris Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Bruce C. Robertson Ph.D. 114 RelationshipsH.I.G. BioVentures, LLC53
James P. Snyder Ph.D. 19 RelationshipsAltiris Therapeutics, Inc.--
Hyunsuk Shim Ph.D. 9 RelationshipsAltiris Therapeutics, Inc.--
Dennis C. Liotta Ph.D. 45 RelationshipsAltiris Therapeutics, Inc.68
Adrian Rawcliffe 57 RelationshipsAdaptimmune Therapeutics plc44
View All Board Members

Altiris Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Advisory Board Ph.D.Dennis C. Liotta45 Relationships4 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
405.9K
Bonus
514.1K
Total Short Term Compensation
594.9K
Total Value of Options
14.4M
Compensation as of Fiscal Year
Altiris Therapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Imprimis Pharmaceuticals, Inc. Announces the Resignation of William H. Nelson as Independent Director and from All Board Committee Positions, Effective Immediately
September 26, 2016 9:00 PM ET
Jounce Therapeutics, Inc. Appoints Stephen Farrand as Chief Technical Officer
September 26, 2016 1:11 PM ET
Nouscom Announces Management Appointments
September 26, 2016 6:00 AM ET
Tyche Industries Ltd Announces the Resignation of G Sandeep as Whole Time Director and Chief Financial Officer
September 24, 2016 12:00 AM ET
Endo International plc Announces Executive Changes
September 23, 2016 11:00 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Altiris Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.